pamrevlumab – Talk Bio

Actionable Insights Powered by AI

FibroGen Lays Off 75% of US Staff After Cancer Drug Fails in Two Phase III Trials

9 months ago talkbio0Tagged Anemia, Antineoplastic Agents, Astellas, AstraZeneca, FibroGen, Neoplasms, pamrevlumab, Pancreatic carcinoma, Pharmacotherapy, Phase 3 Clinical Trials, roxadustat

FibroGen, cancer drug, layoffs, Phase III trials, pamrevlumab, oncology, pancreatic cancer, chemotherapy, anaemia therapy, roxadustat, Astellas, AstraZeneca

FibroGen to Shrink US Workforce by 75% Following More Late-Stage Fails

9 months ago talkbio0Tagged Biotech Layoffs, Clinical Trials, FibroGen, pamrevlumab, Pancreatic carcinoma

FibroGen, workforce reduction, pamrevlumab, clinical trials, biotech layoffs, pancreatic cancer drug